SCHEMBL1140977

SCHEMBL1140977

CCCCCNCC(C)O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.55
ALDH1A1 P00352 1/20 0.55
ANPEP P15144 1/20 0.48
ERAP2 Q6P179 1/20 0.48
EPHX1 P07099 6/20 0.42
MEN1 O00255 1/20 0.41
RAB9A P51151 1/20 0.41
KMT2A Q03164 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
PKM P14618 1/20 0.41
S1PR2 O95136 5/20 0.41
S1PR4 O95977 5/20 0.41
S1PR1 P21453 5/20 0.41
S1PR3 Q99500 5/20 0.41
S1PR5 Q9H228 1/20 0.41
ADH1B P00325 1/20 0.39
ADH1C P00326 1/20 0.39
ADH1A P07327 1/20 0.39
ADH4 P08319 1/20 0.39
ADH7 P40394 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10398805 0.98 ALDH1A1 (0.52) TSHRALDH1A1ANPEPERAP2EPHX1
SCHEMBL8686086 0.98 ALDH1A1 (0.52) TSHRALDH1A1ANPEPERAP2EPHX1
SCHEMBL8685807 0.98 ALDH1A1 (0.52) TSHRALDH1A1ANPEPERAP2EPHX1
SCHEMBL4286294 0.98 ALDH1A1 (0.52) TSHRALDH1A1ANPEPERAP2EPHX1
Water SCHEMBL6655498 0.98 TSHR (0.52) TSHRALDH1A1ANPEPERAP2EPHX1
SCHEMBL8109480 0.98 ALDH1A1 (0.52) TSHRALDH1A1ANPEPERAP2EPHX1
SCHEMBL4141309 0.98 ALDH1A1 (0.52) TSHRALDH1A1ANPEPERAP2EPHX1
SCHEMBL8685954 0.98 ALDH1A1 (0.52) TSHRALDH1A1ANPEPERAP2EPHX1
SCHEMBL21541577 0.98 ALDH1A1 (0.52) TSHRALDH1A1ANPEPERAP2EPHX1
SCHEMBL9949418 0.98 ALDH1A1 (0.52) TSHRALDH1A1ANPEPERAP2EPHX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150367277-A1 Alkanolamine-Based Carbon Dioxide Absorbent Containing Polyalkylene Glycol Monomethyl Ether, and Carbon Dioxide Absorption Method and Separation Method Using Same UNIVERSITY-INDUSTRY COOPERATION FOUNDATION OF KYUNG HEE UNIVERSITY (KR) 2015-12-24 US claimed
US-20040116709-A1 Process for producing optically active n-aryl-1-amino-2-propanol derivatives KANEKA CORPORATION (JP) 2004-06-17 US claimed
EP-1367053-A1 PROCESS FOR PRODUCING OPTICALLY ACTIVE N-ARYL-1-AMINO-2-PROPANOL DERIVATIVES KANEKA CORPORATION (JP) 2003-12-03 EP claimed
EP-0606590-A1 Pharmaceutical or cosmetic composition containing N-acylalcanolamines and N-acylphospho- or lysophospholipids RHONE-POULENC RORER GMBH (DE) 1994-07-20 EP claimed
EP-3367997-B1 NOVEL OCCLUSIVE FORMULATIONS KLINGE CO CHEM PHARM FAB (DE) 2023-12-13 EP disclosed
CN-113616540-B Novel occlusive formulations 株式会社LG生活健康 2023-11-03 CN disclosed
US-11357712-B2 Method of use and compositions LG HOUSEHOLD & HEALTH CARE LTD. (KR) 2022-06-14 US disclosed
US-11337900-B2 Method of use and compositions LG HOUSEHOLD & HEALTH CARE LTD. (KR) 2022-05-24 US disclosed
US-11324686-B2 Occlusive formulations LG HOUSEHOLD & HEALTH CARE LTD. (KR) 2022-05-10 US disclosed
US-11253441-B2 Occlusive compositions LG HOUSEHOLD & HEALTH CARE LTD. (KR) 2022-02-22 US disclosed
CN-108472228-B Novel methods of use and compositions 株式会社LG生活健康 2021-12-07 CN disclosed
CN-113616540-A Novel occlusive formulations 株式会社LG生活健康 2021-11-09 CN disclosed
WO-2002070482-A1 PROCESS FOR PRODUCING OPTICALLY ACTIVE N-ARYL-1-AMINO-2-PROPANOL DERIVATIVES KANEKA CORPORATION (JP) 2002-09-12 WO disclosed
EP-1148051-A2 1,3-dialkyl-2-imidazolidinones and a manufacturing process therefor Mitsui Chemicals, Inc. (JP) 2001-10-24 EP disclosed
EP-1148052-A2 1,3-dialkyl-2-imidazolidinones and a manufacturing process therefor Mitsui Chemicals, Inc. (JP) 2001-10-24 EP disclosed
CN-1256268-A 1,3-dialkyl-2-imidazolinones and its prepn. MITSUI CHEMICALS INC (JP) 2000-06-14 CN disclosed
EP-0992497-A1 1,3-Dialkyl-2-imidazolidinones and a manufacturing process therefor Mitsui Chemicals, Inc. (JP) 2000-04-12 EP disclosed
EP-0882056-A2 PREPARATION OF SURFACE-ACTIVE COMPOUNDS BASED ON LACTOSE COÖPERATIEVE WEIPRODUKTENFABRIEK "BORCULO" W.A. (NL) 1998-12-09 EP disclosed
WO-1997030063-A2 PREPARATION OF SURFACE-ACTIVE COMPOUNDS BASED ON LACTOSE COÖPERATIEVE WEIPRODUKTENFABRIEK 'BORCULO' W.A. (NL) 1997-08-21 WO disclosed
WO-1996028458-A1 SURFACTANT COMPOSITIONS WITH ANTI-MICROBIAL EFFECT CASTROL LIMITED (GB) 1996-09-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11357712-B2 Method of use and compositions CUTA, MGLL, PLIN5 TSHR 4579/4885ALDH1A1 2216/4885ANPEP 3469/4885
US-11337900-B2 Method of use and compositions CUTA, MGLL, PLIN5 TSHR 4648/4885ALDH1A1 2078/4885ANPEP 3384/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.